Sanctuary Advisors LLC Sells 20,700 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT)

Sanctuary Advisors LLC decreased its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 26.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,413 shares of the company’s stock after selling 20,700 shares during the period. Sanctuary Advisors LLC’s holdings in Galectin Therapeutics were worth $73,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GALT. Sovran Advisors LLC purchased a new position in shares of Galectin Therapeutics during the fourth quarter valued at approximately $240,000. Soltis Investment Advisors LLC purchased a new position in Galectin Therapeutics during the 3rd quarter valued at $387,000. Retirement Guys Formula LLC raised its holdings in Galectin Therapeutics by 143.4% in the 4th quarter. Retirement Guys Formula LLC now owns 155,343 shares of the company’s stock worth $200,000 after purchasing an additional 91,526 shares in the last quarter. Kovitz Investment Group Partners LLC bought a new position in Galectin Therapeutics in the 3rd quarter worth $117,000. Finally, Geneos Wealth Management Inc. lifted its position in shares of Galectin Therapeutics by 10.2% in the 4th quarter. Geneos Wealth Management Inc. now owns 388,935 shares of the company’s stock worth $502,000 after purchasing an additional 36,000 shares during the period. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Joel Lewis sold 56,000 shares of Galectin Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total transaction of $49,840.00. Following the completion of the transaction, the chief executive officer now directly owns 897,012 shares in the company, valued at approximately $798,340.68. This trade represents a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jack W. Callicutt sold 40,000 shares of Galectin Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total transaction of $35,600.00. Following the transaction, the chief financial officer now owns 7,614 shares of the company’s stock, valued at $6,776.46. The trade was a 84.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,654 shares of company stock worth $97,456 over the last three months. Company insiders own 50.10% of the company’s stock.

Analysts Set New Price Targets

GALT has been the topic of several research analyst reports. HC Wainwright reiterated a “neutral” rating on shares of Galectin Therapeutics in a research report on Friday, December 27th. StockNews.com lowered shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 30th.

Galectin Therapeutics Price Performance

Shares of GALT opened at $1.60 on Friday. Galectin Therapeutics Inc. has a one year low of $0.73 and a one year high of $4.27. The company has a 50-day simple moving average of $1.29 and a two-hundred day simple moving average of $2.09. The firm has a market capitalization of $100.42 million, a PE ratio of -2.19 and a beta of 0.82.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.